Reported results
- Research and development expenses were $3,062 thousand for the three months ended September 30, 2026, compared with $1,181 thousand for the three months ended September 30, 2025.
- General and administrative expenses were $1,206 thousand for the three months ended September 30, 2026, compared with $1,324 thousand for the three months ended September 30, 2025.
- Net loss was $4,160 thousand, or $0.36 per basic and diluted share, for the three months ended September 30, 2026, compared with $2,392 thousand, or $0.44 per basic and diluted share, for the three months ended September 30, 2025.
- Research and development expenses were $8,936 thousand for the nine months ended September 30, 2026, compared with $3,141 thousand for the nine months ended September 30, 2025.
- Cash and cash equivalents were $10,609 thousand as of September 30, 2026, compared with $21,031 thousand as of December 31, 2025.
Guidance
- Management believes that research and development expenses will continue to increase as the company advances its PH-762 program.
- The planned Phase 2b clinical program is expected to be initiated in the first quarter of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
